Standard Medicare Prescription Drug Benefit, 2013
Standard Medicare Prescription Drug Benefit, 2013 Download Source Kaiser Family Foundation illustration based on CMS standard benefit parameter update for 2013. Amounts rounded to nearest dollar.
View the Latest: Medicare Part D
Filter
-
-
Medicare Part D: A First Look at Plan Offerings in 2015
Issue BriefThis issue brief provides an overview of the Medicare Part D stand-alone prescription drug plan options available in 2015 and key changes from prior years. The analysis examines Part D plan availability, premiums, benefit design features, and low income subsidy plan availability.
-
Medicare Part D 2010 Data Spotlight: Prices for Brand-Name Drugs in the Coverage Gap
Issue BriefThis Medicare Part D data spotlight finds prices for some commonly used brand-name drugs rising in 2010 for beneficiaries who reach the coverage gap (or “doughnut hole”), with increases since 2006 far exceeding the growth in inflation.
-
The Medicare Part D Coverage Gap: Costs and Consequences in 2007
ReportThis study quantifies the number of Medicare Part D plan enrollees in 2007 who reached a gap in their prescription drug coverage known as the “doughnut hole,” as well as the changes in beneficiaries’ use of medications and out-of-pocket spending after they reached that gap.
-
Workforce Reductions at Social Security Could Affect Medicare and Medicaid Coverage
Quick InsightsHow these new workforce reductions at the Social Security Administration will affect people is unknown but could make it harder for people to get connected to benefits they might qualify for…which would in turn affect access to health insurance coverage through Medicare and Medicaid.
-
Medicare Advantage Payments to Increase Again
Quick InsightsThe increase translates into an additional $35 billion to Medicare Advantage plans in 2026 compared to this year….The increase in payments is larger than for 2025 (3.7%) or 2024 (3.3%), but below the increase for 2023 (8.5%), and comes at a time of increasing scrutiny over Medicare Advantage payments.
-
Eliquis’s New Lower Direct-to-Consumer Price is Still Higher Than Medicare’s Negotiated Price
Quick InsightsVoluntary efforts by drug companies to lower prices on selected medications, such as this new discounted price for Eliquis and previous price reductions on certain insulin products, could expand access to lower-priced drugs for some patients, but are not likely to improve prescription drug affordability in the U.S. on a widespread basis.
-
The Trump Administration is Reducing Enhanced Support for the Part D Stand-Alone Drug Plan Market
Quick InsightsIn announcing these changes, CMS states that it is “facilitating the Part D program’s return to operating under regular market conditions.” Increasingly, however, these regular conditions appear unfavorable to the ongoing stability of the stand-alone prescription drug plan market, further tilting the playing field towards Medicare Advantage.
-
What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries
Quick InsightsCMS’s efforts to expand Medicare coverage of GLP-1s for obesity could provide substantial benefits to millions of Medicare beneficiaries, given the potential demand for these highly effective medications…There are potential drawbacks to the short-term program, however.
-
The Current Medicare Prescription Drug Debate: Briefing Charts
ReportThese briefing charts provide background information on prescription drug use and spending among the Medicare population, recent survey data on employers' likely reaction to a Medicare drug benefit, an overview of the proposals for prescription drug coverage passed by the House and Senate at the end of June 2003, and a summary of the key issues to be resolved in the conference. Chart Pack